Eliem Therapeutics Inc

About Eliem Therapeutics Inc

Eliem Therapeutics (NASDAQ: ELYM) is focused on developing treatments that address debilitating and chronic neurological and psychiatric conditions. The company's pipeline includes candidates targeting chronic pain, depression, and epilepsy, aiming to improve the quality of life for those suffering from these conditions. Eliem is advancing its proprietary therapies through clinical trials, leveraging innovative research to deliver novel solutions to unmet medical needs. With an emphasis on patient-centric development, Eliem collaborates with scientific communities and healthcare professionals to ensure its therapies meet the highest standards of efficacy and safety. Their ultimate objective is to bring groundbreaking treatments to market, transforming patient experiences and outcomes in meaningful ways.

What is Eliem Therapeutics Inc known for?

Snapshot

Year founded

Employees

Seattle, United States

Head office

Loading Map...

Operations

All Locations

United States

Products and/or services of Eliem Therapeutics Inc

ETX-123 is a drug candidate focused on treating chronic pain by selectively modulating key voltage-gated sodium channels to potentially offer effective pain relief with fewer side effects.
ETX-155 is an oral GABAA receptor modulator being developed for major depressive disorder and epilepsy, aiming to provide rapid and sustained symptom relief.
Novel ion channel modulators are under development for pain disorders, aiming to target specific ion channels for more precise and safer therapies.
Optimization of a pipeline of neuropsychiatric drugs focuses on treating mood disorders through innovative mechanisms to offer improved patient outcomes.
Research partnerships and collaborations enhance drug discovery efforts and expand development opportunities in therapeutics for pain and mood disorders.
Cutting-edge formulations and delivery technologies are explored to optimize the efficacy and safety profiles of new therapeutic candidates.